摘要
Almost four decades ago,the characterization of the human immunodeficiency virus type 1(HIV-1)genome with the participation of the Haseltine laboratory at Harvard Medical School(Ratner et al.,1985)ushered in the antiretroviral era and established the framework for the genomic-and later multiple omics-based development of targeted antiviral drugs.Battles with pandemic HIV-1 taught us that multitargeted combination antiviral therapy is needed to control pathogens that rapidly adapt to selective pressures from the immune system,vaccines,and therapeutic monoclonal antibodies.
